KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Cash & Equivalents (2016 - 2025)

Biogen has reported Cash & Equivalents over the past 17 years, most recently at $3.0 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $3.0 billion for Q4 2025, up 26.67% from a year ago — trailing twelve months through Dec 2025 was $3.0 billion (up 26.67% YoY), and the annual figure for FY2025 was $3.0 billion, up 26.67%.
  • Cash & Equivalents for Q4 2025 was $3.0 billion at Biogen, down from $3.9 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for BIIB hit a ceiling of $3.9 billion in Q3 2025 and a floor of $1.0 billion in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $2.3 billion (2023), compared with a mean of $2.3 billion.
  • Biggest five-year swings in Cash & Equivalents: crashed 69.29% in 2023 and later surged 141.84% in 2025.
  • Biogen's Cash & Equivalents stood at $2.3 billion in 2021, then skyrocketed by 51.2% to $3.4 billion in 2022, then tumbled by 69.29% to $1.0 billion in 2023, then surged by 126.21% to $2.4 billion in 2024, then rose by 26.67% to $3.0 billion in 2025.
  • The last three reported values for Cash & Equivalents were $3.0 billion (Q4 2025), $3.9 billion (Q3 2025), and $2.8 billion (Q2 2025) per Business Quant data.